Story

Eli Lilly and Novo Nordisk Win Dismissal of GLP-1 Antitrust Lawsuit

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Eli Lilly and Novo Nordisk Win Dismissal of GLP-1 Antitrust Lawsuit
Text size
Background

A federal judge in Texas has dismissed an antitrust lawsuit brought against Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), a significant legal victory for the pharmaceutical giants behind the blockbuster GLP-1 weight-loss drugs. The suit, filed by a compounding pharmacy, alleged the companies engaged in anti-competitive practices to limit the availability of compounded versions of their popular medications.

Court Dismisses Claims

On Thursday, Judge Micaela Alvarez of the U.S. District Court for the Western District of Texas granted a motion from Lilly and Novo Nordisk to dismiss the case. The lawsuit was initiated by Strive Specialties, a compounding pharmacy that accused the drugmakers of violating U.S. antitrust laws.

Strive alleged that Eli Lilly and Novo Nordisk created exclusive partnerships with major telehealth platforms. These agreements, the pharmacy argued, illegally prevented doctors on those platforms from prescribing customized, compounded versions of the GLP-1 drugs, thereby stifling competition.

However, Judge Alvarez ruled that Strive failed to demonstrate it had suffered a legally recognized antitrust injury. The court's decision stated that the compounded GLP-1 products made by Strive do not belong to the same relevant market as the branded drugs sold by the pharmaceutical companies, undermining the core of the antitrust claim.

Sample IUX Markets – In-articleAd

Reactions to the Ruling

The decision drew distinct responses from the parties involved. Eli Lilly, maker of Zepbound (tirzepatide), stated that the "meritless lawsuit should never have been filed against Lilly." The company added that the ruling "confirms that companies engaging in large-scale compounding of tirzepatide are violating the law."

Novo Nordisk, which manufactures Wegovy (semaglutide), also welcomed the court's dismissal of all claims. The company said it will continue to focus on its mission of providing innovative treatments to patients.

Strive Specialties expressed disappointment with the verdict. A representative told media outlets that the company remains confident in its legal position and is currently evaluating its next steps, which could include an appeal.

Read next

More on Stocks
Back to latest news

LATEST